SCHEMBL20228946

SCHEMBL20228946

Cc1nc(CSc2nc3sc(C)c(C)c3c(=O)n2-c2ccccc2)cs1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 5/20 0.64
▸ KMT2A Q03164 5/20 0.64
▸ MEN1 O00255 4/20 0.64
▸ SMN1; SMN2 Q16637 2/20 0.64
▸ TSHR P16473 2/20 0.64
▸ TP53 P04637 1/20 0.62
▸ NPSR1 Q6W5P4 3/20 0.60
▸ CYP1A2 P05177 2/20 0.60
▸ CYP2C9 P11712 2/20 0.60
▸ MAPK10 P53779 1/20 0.60
▸ LMNA P02545 1/20 0.58
▸ ATM Q13315 1/20 0.57
▸ GLA P06280 1/20 0.55
▸ GAA P10253 1/20 0.54
▸ L3MBTL1 Q9Y468 1/20 0.54
▸ RXFP1 Q9HBX9 2/20 0.53
▸ KDM4E B2RXH2 1/20 0.53
▸ HSD17B10 Q99714 1/20 0.53
▸ EGFR P00533 1/20 0.49
▸ POLB P06746 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13407757 0.79 ALDH1A1 (0.69) ALDH1A1KMT2AMEN1SMN1; SMN2TSHR
SCHEMBL13407758 0.79 ALDH1A1 (0.68) ALDH1A1KMT2AMEN1SMN1; SMN2TSHR
SCHEMBL20228922 0.75 ALDH1A1 (0.72) ALDH1A1KMT2AMEN1SMN1; SMN2TSHR
SCHEMBL12281147 0.75 ALDH1A1 (1.00) ALDH1A1KMT2AMEN1SMN1; SMN2TSHR
SCHEMBL20228945 0.73 KMT2A (0.60) ALDH1A1KMT2AMEN1SMN1; SMN2TSHR
SCHEMBL21528229 0.72 ALDH1A1 (0.67) ALDH1A1KMT2AMEN1SMN1; SMN2TSHR
SCHEMBL20228944 0.70 ALDH1A1 (1.00) ALDH1A1KMT2AMEN1SMN1; SMN2TSHR
SCHEMBL20228881 0.69 ALDH1A1 (0.71) ALDH1A1KMT2AMEN1SMN1; SMN2TSHR
SCHEMBL6034989 0.65 TGM2 (0.73) ALDH1A1KMT2AMEN1SMN1; SMN2TSHR
SCHEMBL6034944 0.65 TGM2 (1.00) ALDH1A1KMT2AMEN1TSHRNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12370169-B2 Small molecule Bcl-2 functional converters as cancer therapeutics OREGON STATE UNIVERSITY (US) 2025-07-29 — — US claimed
US-20230129487-A1 SMALL MOLECULE BCL-2 FUNCTIONAL CONVERTERS AS CANCER THERAPEUTICS OREGON STATE UNIVERSITY (US) 2023-04-27 — — US claimed
US-20260014115-A1 SMALL MOLECULE BCL-2 FUNCTIONAL CONVERTERS AS CANCER THERAPEUTICS OREGON STATE UNIVERSITY (US) 2026-01-15 — — US disclosed
US-12370169-B2 Small molecule Bcl-2 functional converters as cancer therapeutics OREGON STATE UNIVERSITY (US) 2025-07-29 — — US disclosed
US-20230129487-A1 SMALL MOLECULE BCL-2 FUNCTIONAL CONVERTERS AS CANCER THERAPEUTICS OREGON STATE UNIVERSITY (US) 2023-04-27 — — US disclosed
US-20230129487-A1 SMALL MOLECULE BCL-2 FUNCTIONAL CONVERTERS AS CANCER THERAPEUTICS OREGON STATE UNIVERSITY (US) 2023-04-27 — — US disclosed
US-20230129487-A1 SMALL MOLECULE BCL-2 FUNCTIONAL CONVERTERS AS CANCER THERAPEUTICS OREGON STATE UNIVERSITY (US) 2023-04-27 — — US disclosed
US-11419843-B2 Small molecule BCL-2 functional converters as cancer therapeutics OREGON STATE UNIVERSITY (US) 2022-08-23 — — US disclosed
US-11419843-B2 Small molecule BCL-2 functional converters as cancer therapeutics OREGON STATE UNIVERSITY (US) 2022-08-23 — — US disclosed
US-20190336469-A1 SMALL MOLECULE BCL-2 FUNCTIONAL CONVERTERS AS CANCER THERAPEUTICS OREGON STATE UNIVERSITY (US) 2019-11-07 — — US disclosed
WO-2018102766-A2 SMALL MOLECULE BCL-2 FUNCTIONAL CONVERTERS AS CANCER THERAPEUTICS OREGON STATE UNIVERSITY (US) 2018-06-07 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260014115-A1 SMALL MOLECULE BCL-2 FUNCTIONAL CONVERTERS AS CANCER THERAPEUTICS BCL2, BAX, BCL2A1 ALDH1A1 3697/4885KMT2A 3281/4885MEN1 2030/4885
US-12370169-B2 Small molecule Bcl-2 functional converters as cancer therapeutics BCL2, BCL2L1, BCL2L13 ALDH1A1 3167/4885KMT2A 3078/4885MEN1 2362/4885
US-11419843-B2 Small molecule BCL-2 functional converters as cancer therapeutics BCL2, BCL2L1, BCL2L13 ALDH1A1 3167/4885KMT2A 3078/4885MEN1 2362/4885
US-20190336469-A1 SMALL MOLECULE BCL-2 FUNCTIONAL CONVERTERS AS CANCER THERAPEUTICS BCL2, BCL2L1, BCL2L13 ALDH1A1 3167/4885KMT2A 3078/4885MEN1 2362/4885
US-20230129487-A1 SMALL MOLECULE BCL-2 FUNCTIONAL CONVERTERS AS CANCER THERAPEUTICS BCL2, BCL2L1, BCL2L13 ALDH1A1 3167/4885KMT2A 3078/4885MEN1 2362/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback